ArticleCureus2023
Sertraline-Induced Optic Nerve Dysfunction.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes a rare case of Sertraline-induced optic nerve dysfunction with optic disc edema (papilledema) in both eyes in a 32-year-old male who was on chronic sertraline therapy for the treatment of generalized anxiety disorder and three panic episodes. The patient was presented to our ophthalmology clinic with two bubbles with dark borders in both eyes on the far side for a few months. An optical coherence tomography showed that retinal nerve fiber layer thickness was 98 microns in OD (right eye) and 105 microns in OS (left eye). Another optical coherence tomography findings in both eyes were the elevation of superior and inferior quadrants. Optical coherence tomography findings supported the diagnosis of optic disc edema (papilledema) in both eyes. Magnetic resonance imaging of the brain revealed symmetrical enlargement in the optic nerves (8 mm in diameter at its thickest point). However, abnormal enhancement was absent, excluding optic neuritis. Sertraline was discontinued and replaced by fluoxetine 20 mg. Five months later, papilledema was resolved. On follow-up one month later, the patient continued to improve in terms of symptoms and test results. The case presented demonstrates a rare association between sertraline use and optic nerve dysfunction. Adding to the increasing number of patients using sertraline worldwide, further research is warranted to investigate the incidence of this association and explore possible pathologic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.